Drug Search Results
More Filters [+]

(18F)AH110690

Alternative Names: (18F)AH110690, ah-110690, ah110690, ah 110690, [18F]AH110690
Latest Update: 2013-12-13
Latest Update Note: Clinical Trial Update

Product Description

an 18F-labeled PIB derivative

Mechanisms of Action: Imaging Agent

Novel Mechanism: No

Modality: Diagnostic Agent

Route of Administration: Intravenous

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: GE Healthcare
Company Location:
Company CEO:
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for (18F)AH110690

Countries in Clinic: Australia

Active Clinical Trial Count: 1

Highest Development Phases

Phase 1: Alzheimer Disease

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

2006-7041-83/hah

P1

Not yet recruiting

Healthy Volunteers|Alzheimer Disease

2020-02-13

Recent News Events

Date

Type

Title